March 9, 2007 - Health Canada warned of the association between Gadolinium-based contrast agents and nephrogenic systemic fibrosis (NSF) and nephrogenic fibrosing dermopathy (NFD) in a letter to healthcare professionals.
Health Canada noted that the majority of NSF/NSD cases occurred after the patient was administered Omniscan, with additional instances following exposure to Magnevist and Optimark.
Warning Alerts Patients to Risk of Gadolinium-Based Contrast Agents
The following gadolinium-based contrast agents are included in the Health Canada warning:
- Magnevist (gadopentetate dimeglumine)
- Omniscan (gadodiamide)
- OptiMARK (gadoversetamide)
- MultiHance (gadobenate dimeglumine)
- ProHance (gadoteridol)
- Gadovist (gadobutrol)
- Vasovist (gadofosveset trisodium)
FDA Warns of Risk Caused by Gadolinium-Based Contrast Agents
May 23, 2007Gadolinium-based contrast agents now must carry a black box warning due to the risk of a potentially fatal disease.
Patients with kidney disease or chronic liver disease risk developing nephrogenic systemic fibrosis. This disease is characterized by the thickening of skin and connective tissues, inhibiting a person's ability to move. Nephrogenic systemic fibrosis can be fatal.
The FDA first warned medical providers of a link between gadolinium-based agents and nephrogenic systemic fibrosis in June 2006. The warning was updated in December 2006.
The agency stated it was aware of at least 128 reports of nephrogenic systemic fibrosis in patients who were administered a gadolinium-based contrast agent.
About Gadolinium Contrast Agents
Contrast agents commonly are used during medical imaging procedures to highlight specific parts of the body, making them easier to see.
Gadolinium is a metal ion administered to patients undergoing magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) to provide a clearer picture of organs and tissues
Gadolinium Lawyers Canada
Greg Monforton and Partners is investigating legal claims against on behalf of Canadians who developed nephrogenic systemic fibrosis after being administered a gadolinium-based contrast agent.
If you or a loved one has been harmed by a Gadolinium contrast agent, we encourage you to contact us. We will represent clients throughout Canada in lawsuits against the manufacturers of these contrast agents.
For free answers to your questions about Gadolinium contrast agents, please complete our online form.